Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | SENIOR VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 22,857 |
Reported balance
After 2023-02-28 transaction · row 1
1 source rowRow 1 · 2023-02-28 · Tax withholding · Disposed 1,024 · Balance 22,857 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2023 Filed Mar 3, 2023 00:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,024 | $99.77 | $102,164.48 |
DisclosureSEC source: 0001415889-23-003911 · form4-03032023_120355.xml · nonDerivative · entry 1 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,857 Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 00:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 664 | $106.74 | $70,875.36 |
DisclosureSEC source: 0001415889-23-003056 · form4-02232023_120236.xml · nonDerivative · entry 3 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,881 Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 00:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 518 | $106.74 | $55,291.32 |
DisclosureSEC source: 0001415889-23-003056 · form4-02232023_120236.xml · nonDerivative · entry 2 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,545 Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 41,648 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003056 · form4-02232023_120236.xml · derivative · entry 4 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,648 Underlying: Common Shares · 41,648 shares Expires 2033-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,882 on February 17, 2024, 13,883 on February 17, 2025, and 13,883 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003056 · form4-02232023_120236.xml · nonDerivative · entry 1 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,063 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 26, 2022 Filed Jul 27, 2022 21:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,457 | $109.05 | $267,942.98 |
DisclosureSEC source: 0001415889-22-008001 · form4-07272022_020700.xml · nonDerivative · entry 1 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,503 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.04 to $109.055, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 01:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 886 | $116.79 | $103,475.94 |
DisclosureSEC source: 0001415889-22-001741 · form4-02232022_050219.xml · nonDerivative · entry 4 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,960 Read SEC document |
| February 21, 2022 Filed Feb 24, 2022 01:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 701 | $116.79 | $81,869.79 |
DisclosureSEC source: 0001415889-22-001741 · form4-02232022_050219.xml · nonDerivative · entry 3 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,846 Read SEC document |
| February 19, 2022 Filed Feb 24, 2022 01:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 595 | $116.79 | $69,490.05 |
DisclosureSEC source: 0001415889-22-001741 · form4-02232022_050219.xml · nonDerivative · entry 2 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,547 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 48,852 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001741 · form4-02232022_050219.xml · derivative · entry 5 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,852 Underlying: Common Shares · 48,852 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,284 on February 18, 2023, 16,284 on February 18, 2024, and 16,284 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001741 · form4-02232022_050219.xml · nonDerivative · entry 1 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,142 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.